NeurologyLive

Happy September! A new month can only mean one thing: a new edition of #TheAxon newsletter! Check out (almost) everything our team covered in the month of August:

Here is a look at our news coverage so far from #CTAD24 this week in Madrid, Spain! 🇪🇸💃🌞 🗞️ Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development (https://lnkd.in/em8AxUwu) 🗞️ Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery (https://lnkd.in/eafmbxhT) 🎥 Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc (https://lnkd.in/esQRx7wG) 🎥 Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD (https://lnkd.in/eFHTYUz3) More coverage is on the way, stay tuned! #Alzheimers CTAD Clinical Trials on Alzheimer's Disease

Want to stay up-to-date with the latest data and expert insights in #Alzheimers at #CTAD24? Be sure then to check out our coverage here and follow along 👉https://lnkd.in/eRnUwHh2 CTAD Clinical Trials on Alzheimer's Disease

Everyone is busy attending sessions and poster presentations here in Madrid, Spain for Day 2 of #CTAD24! 🇪🇸🌞 #Alzheimers CTAD Clinical Trials on Alzheimer's Disease

🫣📹 Here is a quick look at the interview that we recently did with Lars Lannfelt, MD, PhD, professor of molecular geriatrics at Uppsala University, this afternoon at #CTAD24! Be on the lookout for more clips from interviews this week during the meeting! CTAD Clinical Trials on Alzheimer's Disease BioArctic

Our last interview for Day 2 of #CTAD24 was with Lars Lannfelt, MD, PhD, professor of molecular geriatrics at Uppsala University, who provided an overview of his keynote presentation titled "Lecanemab: from mutation to a treatment for Alzheimer's disease." Stay tuned for the video from the conversation! 🧠💊 CTAD Clinical Trials on Alzheimer's Disease BioArctic

New findings from the phase 3b TRAILBLAZER-ALZ-6 trial showed that an enhanced titration dosing regimen of donanemab led to significant reductions in the frequency and severity of amyloid-related imaging abnormalities-edema. Eli Lilly #CTAD24 #Alzheimers CTAD Clinical Trials on Alzheimer's Disease https://lnkd.in/eafmbxhT

🫣🎥 Here is also a sneak peek at the conversation we had with Brent Forester, MD, MSc, of Tufts University School of Medicine, at #CTAD24 this morning! He highlighted some topics that he considered important for the field of #Alzheimers in regard to this year's meeting. 🇪🇸🌞 CTAD Clinical Trials on Alzheimer's Disease

🫣📹Here is a sneak peek at the interview we did with Michael Woodward, MD, FRACP, head of dementia research at Austin Health, and Anthony Caggiano, MD, PhD, CMO at Cognition Therapeutics, Inc., who both shared their perspective on the latest presentations in #Alzheimers at #CTAD24! CTAD Clinical Trials on Alzheimer's Disease

🇪🇸🧠 We also spoke with Brent Forester, MD, MSc, of Tufts University School of Medicine, this morning at #CTAD24! In the conversation, he shared his clinical perspective on the THC-AD study assessing dronabinol treatment for agitation in #Alzheimers dementia. Stay tuned for the video interview coming soon! 🎥🗣️ CTAD Clinical Trials on Alzheimer's Disease